The global pharmaceutical market wasn’t always as regulated as it is today. As pharmaceutical companies raced to bring their products to consumers, they faced duplicated efforts, wasted resources, increased costs, and inconsistent regulations. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was established in 1990 to harmonize global pharmaceutical regulatory standards and combat these issues. These ICH guidelines have since become the standard in pharmaceutical development and validation for over thirty years, ensuring the safety, efficacy, and quality of life-saving drugs.
Stability testing has become one of the most critical processes regulated by the ICH. As pharmaceuticals make their way to market through the global supply chain, ICH stability guidelines help manufacturers analyze how temperature, humidity, and light affect the quality of their products, helping them determine both shelf-life and optimal storage conditions.
Why ICH Stability Testing?
The FDA and the EMA require ICH stability testing as part of their drug approval process. Stability testing ensures product quality throughout its lifecycle. It provides data-driven evidence into how various environmental factors impact drug integrity, from production to patient use, protecting consumers from illness or death linked to degraded formulations.
But that’s not all. ICH stability testing also helps:
- Identify & optimize ideal formulations
- Determine appropriate packaging materials and container closure systems
- Provide data to support labeling claims and storage recommendations
ICH stability testing is more than just a regulation. It’s a comprehensive approach that upholds industry standards and protects patient health.
There are three key ICH guidelines for stability testing. Let’s explore how these regulations safeguard patient health.
ICH Q1A: New Drug Products
ICH Q1A is the primary ICH guideline regulating stability storage. Entitled “Stability Testing of New Drug Substances and Products,” this guideline establishes recommended storage conditions for new pharmaceuticals, helps determine shelf-life, and ensures consistency across batches.
Guiding principles include:
- Stability studies should cover physical, chemical, biological, and microbiological attributes.
- Testing should be conducted on at least three primary batches.
- The batches should be manufactured using methods representative of the final commercial process.
- Analytical procedures must be validated and stability-indicating.
Stability storage conditions per ICH guidelines are:
- Long-term: 25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH
- Intermediate: 30°C ± 2°C/65% RH ± 5% RH
- Accelerated: 40°C ± 2°C/75% RH ± 5% RH
To ensure quality and stability, a new drug product should undergo testing every 3 months in the first year, every 6 months in the second year, and then annually. However, in the rush to release products, sometimes pharmaceutical manufacturers turn to accelerated aging instead of real-time aging. In this case, the ICH requires a minimum of three time points (1, 3, and 6 months) in a 6-month study.
ICH Q1C: New Dosage Forms
Sometimes pharmaceutical products maintain their active ingredients, but their route of administration or delivery changes. For example, an oral drug may later become a parenteral. Or a capsule product may become a tablet product. ICH guideline Q1C is the guiding principle in this instance.
In these cases, the ICH guidelines established in ICH Q1A, covering batch selection, storage conditions, and testing frequency, remain the same.
In some instances, ICH guidelines allow for reduced stability testing. This typically includes 6 months of accelerated stability data and 6 months of long-term stability data.
ICH Q1D: Bracketing and Matrixing
There are many variations to a singular drug product. For example, one product may have four or five different strengths or three or four different package sizes/fill varies. To help manufacturers save time and resources, ICH guidelines allow for a technique called Bracketing and Matrixing under Q1D.
In Bracketing, only samples at the extremes are tested. For example, if a product comes in 5, 10, or 15mg tablets, only the 5mg and the 15mg need to be tested. It is assumed that the intermediate levels are represented in the extremes.
Matrixing is when a subset of samples for all factor combinations is tested at specific time points. This is most applicable for drugs in later stages of development that may have already undergone stability testing or following market authorization.
ICH Stability Storage with Purple Diamond
ICH guidelines have revolutionized the pharmaceutical industry by establishing a unified framework for evaluating how environmental factors like temperature, humidity, and light impact product integrity. By setting global standards for stability testing, these guidelines have enhanced product quality, ensured regulatory consistency, and, most importantly, safeguarded patient safety.
If you’re looking for stability storage support, our team at Purple Diamond has provided stability storage per ICH guidelines for nearly two decades. Our state-of-the-art chambers, advanced monitoring systems, and ISO-certified laboratories ensure reliable and accurate results, whether you’re conducting real-time stability testing, accelerated aging studies, or customized storage protocols.
Partnering with Purple Diamond means you’ll benefit from expert guidance, cutting-edge technology, and a commitment to excellence in every stage of the stability testing process.
Let us help you safeguard the integrity of your products and ensure their success in the global market. Contact us today to learn more about our comprehensive ICH stability storage services and how we can support your product’s journey from development to distribution.